VIGL vs. MOLN, LIFE, SGMO, DBVT, OMGA, XFOR, BCAB, CRDL, VXRT, and BLUE
Should you be buying Vigil Neuroscience stock or one of its competitors? The main competitors of Vigil Neuroscience include Molecular Partners (MOLN), aTyr Pharma (LIFE), Sangamo Therapeutics (SGMO), DBV Technologies (DBVT), Omega Therapeutics (OMGA), X4 Pharmaceuticals (XFOR), BioAtla (BCAB), Cardiol Therapeutics (CRDL), Vaxart (VXRT), and bluebird bio (BLUE). These companies are all part of the "biological products, except diagnostic" industry.
Vigil Neuroscience (NASDAQ:VIGL) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations.
Vigil Neuroscience has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Vigil Neuroscience currently has a consensus price target of $17.20, indicating a potential upside of 419.64%. Molecular Partners has a consensus price target of $4.50, indicating a potential upside of 18.42%. Given Vigil Neuroscience's stronger consensus rating and higher probable upside, research analysts plainly believe Vigil Neuroscience is more favorable than Molecular Partners.
83.6% of Vigil Neuroscience shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 33.0% of Vigil Neuroscience shares are owned by insiders. Comparatively, 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Vigil Neuroscience had 1 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Vigil Neuroscience and 2 mentions for Molecular Partners. Vigil Neuroscience's average media sentiment score of 1.88 equaled Molecular Partners'average media sentiment score.
Molecular Partners has higher revenue and earnings than Vigil Neuroscience. Molecular Partners is trading at a lower price-to-earnings ratio than Vigil Neuroscience, indicating that it is currently the more affordable of the two stocks.
Vigil Neuroscience has a net margin of 0.00% compared to Molecular Partners' net margin of -864.73%. Molecular Partners' return on equity of -31.42% beat Vigil Neuroscience's return on equity.
Vigil Neuroscience received 7 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 75.00% of users gave Vigil Neuroscience an outperform vote while only 44.00% of users gave Molecular Partners an outperform vote.
Summary
Vigil Neuroscience beats Molecular Partners on 12 of the 16 factors compared between the two stocks.
Get Vigil Neuroscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vigil Neuroscience Competitors List
Related Companies and Tools
